CD8A and cancer: Another study by the same group explored LNP-based LN-targeting delivery systems, demonstrating improved cytotoxic CD8+ T cell responses and enhanced protective effects against melanoma, indicative of the system’s potential as a platform for future mRNA cancer vaccines.